AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and early-stage clinical assets across a host of ... Read More
ENB Therapeutics completes Phase 1 trial enrollment for ENB-003
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
Biocytogen signs antibody license agreement with Pheon Therapeutics
Biocytogen Pharmaceuticals, a global biotech firm specialising in novel antibody therapeutics, has agreed to a licensing deal with Pheon Therapeutics, an antibody-drug conjugate (ADC) developer. ... Read More
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in ... Read More
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca's IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the ... Read More
ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer
ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone with its flagship drug candidate evorpacept securing ... Read More
Natco Pharma wins FDA approval for generic colorectal cancer drug
Indian pharmaceutical firm Natco Pharma has gained the US Food and Drug Administration (FDA)'s final approval for its abbreviated new drug application (ANDA) for Tipiracil ... Read More
MEDiC Life Sciences, Bristol Myers Squibb to advance discovery of tumor targets
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a research collaboration with pharmaceutical giant Bristol Myers Squibb to advance the discovery ... Read More